A Phase I/II, First-in-Human (FIH), Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-24C5 in Patients with Advanced Solid Tumors
| Protocol No. | CTO-LM24C5-01-101 | Scope | National |
|---|---|---|---|
| Principal Investigator | Mateusz Opyrchal | Treatment Type | Treatment |
| Age Group | Adult | Phase | Phase I/II |
